Mast cell activation symptoms are prevalent in Long-COVID

Objectives: Hyper-inflammation caused by COVID-19 may be mediated by mast cell activation (MCA) which has also been hypothesized to cause Long-COVID (LC) symptoms. We determined prevalence/severity of MCA symptoms in LC. Methods: Adults in LC-focused Facebook support groups were recruited for online...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Leonard B. Weinstock, Jill B. Brook, Arthur S. Walters, Ashleigh Goris, Lawrence B. Afrin, Gerhard J. Molderings
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	COVID-19 Long-COVID mast cell activation fatigue Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/db453fa00119469cb16d24c614ced8ea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:db453fa00119469cb16d24c614ced8ea
record_format	dspace
spelling	oai:doaj.org-article:db453fa00119469cb16d24c614ced8ea2021-11-30T04:14:21ZMast cell activation symptoms are prevalent in Long-COVID1201-971210.1016/j.ijid.2021.09.043https://doaj.org/article/db453fa00119469cb16d24c614ced8ea2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1201971221007517https://doaj.org/toc/1201-9712Objectives: Hyper-inflammation caused by COVID-19 may be mediated by mast cell activation (MCA) which has also been hypothesized to cause Long-COVID (LC) symptoms. We determined prevalence/severity of MCA symptoms in LC. Methods: Adults in LC-focused Facebook support groups were recruited for online assessment of symptoms before and after COVID-19. Questions included presence and severity of known MCA and LC symptoms and validated assessments of fatigue and quality of life. General population controls and mast cell activation syndrome (MCAS) patients were recruited for comparison if they were ≥18 years of age and never had overt COVID-19 symptoms. Results: There were 136 LC subjects (89.7% females, age 46.9 ±12.9 years), 136 controls (65.4% females, age 49.2 ±15.5), and 80 MCAS patients (85.0% females, age 47.7 ±16.4). Pre-COVID-19 LC subjects and controls had virtually identical MCA symptom and severity analysis. Post-COVID-19 LC subjects and MCAS patients prior to treatment had virtually identical MCA symptom and severity analysis. Conclusions: MCA symptoms were increased in LC and mimicked the symptoms and severity reported by patients who have MCAS. Increased activation of aberrant mast cells induced by SARS-CoV-2 infection by various mechanisms may underlie part of the pathophysiology of LC, possibly suggesting routes to effective therapy.Leonard B. WeinstockJill B. BrookArthur S. WaltersAshleigh GorisLawrence B. AfrinGerhard J. MolderingsElsevierarticleCOVID-19Long-COVIDmast cell activationfatigueInfectious and parasitic diseasesRC109-216ENInternational Journal of Infectious Diseases, Vol 112, Iss , Pp 217-226 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 Long-COVID mast cell activation fatigue Infectious and parasitic diseases RC109-216
spellingShingle	COVID-19 Long-COVID mast cell activation fatigue Infectious and parasitic diseases RC109-216 Leonard B. Weinstock Jill B. Brook Arthur S. Walters Ashleigh Goris Lawrence B. Afrin Gerhard J. Molderings Mast cell activation symptoms are prevalent in Long-COVID
description	Objectives: Hyper-inflammation caused by COVID-19 may be mediated by mast cell activation (MCA) which has also been hypothesized to cause Long-COVID (LC) symptoms. We determined prevalence/severity of MCA symptoms in LC. Methods: Adults in LC-focused Facebook support groups were recruited for online assessment of symptoms before and after COVID-19. Questions included presence and severity of known MCA and LC symptoms and validated assessments of fatigue and quality of life. General population controls and mast cell activation syndrome (MCAS) patients were recruited for comparison if they were ≥18 years of age and never had overt COVID-19 symptoms. Results: There were 136 LC subjects (89.7% females, age 46.9 ±12.9 years), 136 controls (65.4% females, age 49.2 ±15.5), and 80 MCAS patients (85.0% females, age 47.7 ±16.4). Pre-COVID-19 LC subjects and controls had virtually identical MCA symptom and severity analysis. Post-COVID-19 LC subjects and MCAS patients prior to treatment had virtually identical MCA symptom and severity analysis. Conclusions: MCA symptoms were increased in LC and mimicked the symptoms and severity reported by patients who have MCAS. Increased activation of aberrant mast cells induced by SARS-CoV-2 infection by various mechanisms may underlie part of the pathophysiology of LC, possibly suggesting routes to effective therapy.
format	article
author	Leonard B. Weinstock Jill B. Brook Arthur S. Walters Ashleigh Goris Lawrence B. Afrin Gerhard J. Molderings
author_facet	Leonard B. Weinstock Jill B. Brook Arthur S. Walters Ashleigh Goris Lawrence B. Afrin Gerhard J. Molderings
author_sort	Leonard B. Weinstock
title	Mast cell activation symptoms are prevalent in Long-COVID
title_short	Mast cell activation symptoms are prevalent in Long-COVID
title_full	Mast cell activation symptoms are prevalent in Long-COVID
title_fullStr	Mast cell activation symptoms are prevalent in Long-COVID
title_full_unstemmed	Mast cell activation symptoms are prevalent in Long-COVID
title_sort	mast cell activation symptoms are prevalent in long-covid
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/db453fa00119469cb16d24c614ced8ea
work_keys_str_mv	AT leonardbweinstock mastcellactivationsymptomsareprevalentinlongcovid AT jillbbrook mastcellactivationsymptomsareprevalentinlongcovid AT arthurswalters mastcellactivationsymptomsareprevalentinlongcovid AT ashleighgoris mastcellactivationsymptomsareprevalentinlongcovid AT lawrencebafrin mastcellactivationsymptomsareprevalentinlongcovid AT gerhardjmolderings mastcellactivationsymptomsareprevalentinlongcovid
_version_	1718406833494818816

Mast cell activation symptoms are prevalent in Long-COVID

Ejemplares similares